Spots Global Cancer Trial Database for pertuzumab
Every month we try and update this database with for pertuzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | NCT01855828 | Her2-Positive B... | Pertuzumab Trastuzumab Paclitaxel 5-fluorouracil Epirubicin Cyclophosphamid... | 18 Years - 65 Years | Yale University | |
| Cardiac Safety Study in Patients With HER2 + Breast Cancer | NCT01904903 | HER2 Positive B... Left Ventricula... | Trastuzumab Pertuzumab Ado Trastuzumab... | 18 Years - 120 Years | Medstar Health Research Institute | |
| A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. | NCT00545688 | Breast Cancer | Herceptin Docetaxel Pertuzumab | 18 Years - | Hoffmann-La Roche | |
| A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | NCT00781612 | Neoplasm Metast... | Docetaxel Paclitaxel Pertuzumab Trastuzumab Trastuzumab Emt... Atezolizumab | 18 Years - | Genentech, Inc. | |
| NSABP Biospecimen Discovery Project | NCT01850628 | Breast Cancer | Paclitaxel trastuzumab pertuzumab | 18 Years - | NSABP Foundation Inc | |
| Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer | NCT02827877 | HER2 Positive B... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Copper Cu 64-DO... Laboratory Biom... Pertuzumab Positron Emissi... Therapeutic Con... Trastuzumab | 18 Years - | City of Hope Medical Center | |
| A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer | NCT01491737 | Breast Cancer | Pertuzumab Trastuzumab Aromatase Inhib... Induction Chemo... | 18 Years - | Hoffmann-La Roche | |
| A Study of Pertuzumab in Participants With Prostate Cancer | NCT02480010 | Prostate Cancer | Pertuzumab | 19 Years - | Hoffmann-La Roche | |
| TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer | NCT05188313 | Esophageal Canc... Esophageal Aden... | Trastuzumab Pertuzumab Paclitaxel Carboplatin | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | NCT04208178 | Advanced HER2+B... | Alpelisib Alpelisib match... Trastuzumab Pertuzumab | 18 Years - | Novartis | |
| Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib | NCT01875666 | Breast Neoplasm... | Trastuzumab pertuzumab lapatinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer | NCT04419181 | HER2-positive B... | Docetaxel Carboplatin Trastuzumab Pertuzumab Trastuzumab emt... | 18 Years - | University of Rochester | |
| Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients | NCT04253561 | Metastatic Brea... | Ipatasertib Trastuzumab Pertuzumab | 18 Years - | SOLTI Breast Cancer Research Group | |
| Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | NCT02252887 | Metastatic HER2... | Gemcitabine Trastuzumab Pertuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients | NCT02910219 | Breast Cancer | Crofelemer | 18 Years - | Georgetown University | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | NCT02947685 | HER-2 Positive ... Estrogen Recept... | palbociclib trastuzumab pertuzumab letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | Alliance Foundation Trials, LLC. | |
| A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer | NCT02004093 | Ovarian Cancer | pertuzumab paclitaxel gemcitabine carboplatin | 18 Years - | Hoffmann-La Roche | |
| Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | NCT03125928 | HER2-positive B... | Atezolizumab Paclitaxel Trastuzumab Pertuzumab | 18 Years - | Fox Chase Cancer Center | |
| A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | NCT01966471 | Breast Cancer | Trastuzumab Emt... Trastuzumab Pertuzumab Paclitaxel Epirubicin Doxorubicin Docetaxel Cyclophosphamid... 5-Fluorouracil | 18 Years - | Hoffmann-La Roche | |
| A Study for the Neoadjuvant Treatment of Breast Cancer | NCT05420454 | Breast Cancer | Docetaxel Carboplatin Trastuzumab Pertuzumab Nab paclitaxel Epirubicin Cyclophosphamid... Docetaxel Epirubicin Cyclophosphamid... Nab paclitaxel | 18 Years - | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. | NCT05838066 | First-line Trea... | KN026 HB1801 Pertuzumab Trastuzumab Docetaxel | 18 Years - | Shanghai JMT-Bio Inc. | |
| Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy | NCT05180006 | Breast Cancer | Atezolizumab In... Bevacizumab Pertuzumab Trastuzumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | NCT05113251 | Breast Neoplasm... Breast Cancer HER2-positive E... | Trastuzumab Der... Paclitaxel Trastuzumab Pertuzumab Doxorubicin cyclophosphamid... | 18 Years - | AstraZeneca | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial | NCT06278870 | HER2-positive M... First-line Trea... | disitamab vedot... Pyrotinib trastuzumab Pertuzumab taxane drug | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | NCT02060253 | HER2-positive B... Male Breast Can... Recurrent Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | ganetespib paclitaxel trastuzumab pertuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | NCT03365882 | Colon Adenocarc... ERBB2 Gene Ampl... Rectal Adenocar... Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... | Cetuximab Irinotecan Hydr... Laboratory Biom... Pertuzumab Trastuzumab HER-2 testing | 18 Years - | SWOG Cancer Research Network | |
| Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients | NCT03144947 | Cancer, Breast | Trastuzumab IV Trastuzumab SC Pertuzumab Docetaxel | 18 Years - | Gruppo Oncologico Italiano di Ricerca Clinica | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine | NCT00833963 | Breast Cancer Pregnancy | Trastuzumab Pertuzumab Ado-Trastuzumab... | 18 Years - | Genentech, Inc. | |
| Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab | NCT03135171 | Breast Cancer | Trastuzumab Pertuzumab Tocilizumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer | NCT01572038 | Breast Neoplasm... | Docetaxel Nab-paclitaxel Paclitaxel Pertuzumab Trastuzumab | 18 Years - | Hoffmann-La Roche | |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer | NCT04108858 | Anatomic Stage ... HER2-Positive B... Metastatic Brea... | Copanlisib Pertuzumab Trastuzumab | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | NCT03199885 | Metastatic Brea... Metastatic HER2... Recurrent Breas... Recurrent HER2-... Stage III Breas... Stage IV Breast... Unresectable Br... Unresectable HE... | Atezolizumab Biopsy Bone Scan Computed Tomogr... Docetaxel Magnetic Resona... Paclitaxel Pertuzumab Placebo Adminis... Quality-of-Life... Trastuzumab | 18 Years - | National Cancer Institute (NCI) | |
| Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | NCT02229149 | Breast Neoplasm... Malignant Tumor... | Trastuzumab Pertuzumab Vinorelbine, Pa... | 18 Years - | US Oncology Research | |
| Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer | NCT02625441 | Breast Cancer | Pertuzumab Trastuzumab | 18 Years - | Helsinki University Central Hospital | |
| Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer | NCT01048099 | Breast Cancer | PRO Onc Assay a... Trastuzumab Pertuzumab | 18 Years - | SCRI Development Innovations, LLC | |
| Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | NCT01121939 | Neuroendocrine ... | Bevacizumab Pertuzumab Sandostatin LAR... | 18 Years - | SCRI Development Innovations, LLC | |
| Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab | NCT00301899 | Breast Cancer | pertuzumab trastuzumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | NCT04784715 | Breast Cancer; ... | Trastuzumab der... Placebo Taxane Pertuzumab Trastuzumab | 18 Years - 130 Years | AstraZeneca | |
| A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer | NCT01674062 | Breast Cancer | Pertuzumab Trastuzumab | 18 Years - | Hoffmann-La Roche | |
| Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy | NCT04578106 | HER2-positive B... Stage I Breast ... | Trastuzumab and... | 40 Years - | Fundacio Clinic Barcelona | |
| A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer | NCT03811418 | Advanced Breast... HER2-positive B... | Trastuzumab Pertuzumab Vinorelbine Docetaxel | 18 Years - | iOMEDICO AG | |
| Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel | NCT04514419 | Breast Cancer | HS627 Pertuzumab | 18 Years - | BioRay Pharmaceutical Co., Ltd. | |
| A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | NCT03264547 | Breast Cancer | Pertuzumab Trastuzumab Docetaxel Paclitaxel Eribulin | 20 Years - 70 Years | Japan Breast Cancer Research Group | |
| Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer | NCT06038539 | HR Negative HER... | PERT-IJS plus t... Perjeta plus tr... | 18 Years - 99 Years | Biocon Limited | |
| A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer | NCT01461057 | Gastric Cancer | Capecitabine Cisplatin Pertuzumab Pertuzumab Trastuzumab | 18 Years - | Hoffmann-La Roche | |
| Observational Study of Pertuzumab Safety in Participants With Breast Cancer | NCT02266173 | Breast Cancer | Pertuzumab | 18 Years - | Hoffmann-La Roche | |
| Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | NCT01121939 | Neuroendocrine ... | Bevacizumab Pertuzumab Sandostatin LAR... | 18 Years - | SCRI Development Innovations, LLC | |
| Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | NCT05020860 | Breast Cancer Breast Neoplasm Breast Cancer F... Breast Cancer I... Breast Cancer S... Breast Cancer S... Triple Negative... Hormone Recepto... HER2-positive B... Triple Negative... Estrogen Recept... | Paclitaxel Carboplatin Trastuzumab Pertuzumab Doxorubicin Cyclophosphamid... Pembrolizumab Pertuzumab/Tras... | 18 Years - | Baylor Breast Care Center | |
| Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | NCT01855828 | Her2-Positive B... | Pertuzumab Trastuzumab Paclitaxel 5-fluorouracil Epirubicin Cyclophosphamid... | 18 Years - 65 Years | Yale University | |
| Trastuzumab & Pertuzumab Followed by T-DM1 in MBC | NCT01835236 | Metastatic Brea... | Trastuzumab Pertuzumab Paclitaxel Vinorelbine T-DM1 | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | NCT02057133 | Breast Neoplasm... | LY2835219 Letrozole Anastrozole Tamoxifen Exemestane Everolimus Trastuzumab LY3023414 Fulvestrant Pertuzumab Loperamide Endocrine thera... | 18 Years - | Eli Lilly and Company | |
| Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | NCT02390427 | Metastatic Brea... Recurrent Breas... | Taselisib Trastuzumab emt... Pertuzumab Trastuzumab Paclitaxel | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) | NCT01026142 | Breast Cancer | Capecitabine Capecitabine Pertuzumab Trastuzumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | NCT01358877 | Breast Cancer | 5-Fluorouracil Carboplatin Cyclophosphamid... Docetaxel Doxorubicin Epirubicin Paclitaxel Pertuzumab Placebo Trastuzumab | 18 Years - | Hoffmann-La Roche | |
| Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy | NCT01847001 | Locally Advance... Breast Cancer | Propranolol DOT imaging Paclitaxel Nab-paclitaxel Trastuzumab Pertuzumab Doxorubicin Cyclophosphamid... Surgery Premedication Anti-nausea the... Pegfilgrastim | 18 Years - | Columbia University | |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | NCT02125344 | Tubular Breast ... Tubular Breast ... Mucinous Breast... Breast Cancer F... Invasive Ductal... HER2 Positive B... Inflammatory Br... | non-pegylated l... Carboplatin Paclitaxel Epirubicin Cyclophosphamid... Pertuzumab Trastuzumab Ferric carboxym... | 18 Years - | German Breast Group | |
| Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy | NCT01847001 | Locally Advance... Breast Cancer | Propranolol DOT imaging Paclitaxel Nab-paclitaxel Trastuzumab Pertuzumab Doxorubicin Cyclophosphamid... Surgery Premedication Anti-nausea the... Pegfilgrastim | 18 Years - | Columbia University | |
| Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer | NCT04337658 | HER2-positive B... | Pertuzumab Trastuzumab Fulvestrant Capecitabine | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | NCT03304080 | Breast Neoplasm... Breast Diseases | Anastrozole Palbociclib Trastuzumab Pertuzumab | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) | NCT01684878 | Ovarian Cancer | Gemcitabine (Ch... Paclitaxel (Che... Pertuzumab Placebo Topotecan (Chem... | 18 Years - | Hoffmann-La Roche | |
| A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol | NCT01817452 | Breast Cancer | Trastuzumab Pertuzumab Paclitaxel | 18 Years - | West German Study Group | |
| A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | NCT04158258 | Breast Cancer | Bevacizumab Trastuzumab Ado-trastuzumab... Pertuzumab Atezolizumab Capecitabine | 18 Years - | Hoffmann-La Roche | |
| Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy | NCT04578106 | HER2-positive B... Stage I Breast ... | Trastuzumab and... | 40 Years - | Fundacio Clinic Barcelona | |
| A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer | NCT00934856 | Breast Cancer | Docetaxel Pertuzumab Trastuzumab emt... | 18 Years - | Hoffmann-La Roche | |
| Omission of Radiation in Patients With Her-2 Positive Breast Cancer | NCT03460067 | HER2-positive B... | Omission of Rad... | 40 Years - | University of Kansas Medical Center | |
| A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy | NCT02536339 | Metastatic Brea... | Pertuzumab Trastuzumab | 18 Years - | Genentech, Inc. | |
| Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer | NCT06038539 | HR Negative HER... | PERT-IJS plus t... Perjeta plus tr... | 18 Years - 99 Years | Biocon Limited | |
| A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer | NCT05132582 | HER2 Positive B... | Tucatinib Trastuzumab Pertuzumab Combination pro... Placebo | 18 Years - | Seagen Inc. | |
| A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | NCT02336984 | Breast Cancer | HER-2 pulsed DC... trastuzumab pertuzumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer | NCT05883852 | HER2 Positive E... | Docetaxel carboplatin Trastuzumab Pertuzumab Epirubicin cyclophosphamid... | 18 Years - 70 Years | Fudan University | |
| To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | NCT03006172 | Breast Cancer Solid Tumor | Inavolisib Fulvestrant Letrozole Palbociclib Metformin Trastuzumab Pertuzumab | 18 Years - | Genentech, Inc. | |
| Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC | NCT03417544 | HER2-positive M... Central Nervous... | ATEZOLIZUMAB PERTUZUMAB TRASTUZUMAB | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer | NCT00976989 | Breast Cancer | Pertuzumab Trastuzumab FEC Docetaxel TCH | 18 Years - | Hoffmann-La Roche | |
| ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | NCT04172259 | Breast Cancer Neoadjuvant Che... | Doxorubicin lip... Cyclophosphamid... Trastuzumab Docetaxel Epirubicin Pertuzumab Paclitaxel Paclitaxel-albu... | 18 Years - 70 Years | Sun Yat-sen University | |
| Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer | NCT04717531 | Breast Cancer | Pyrotinib Trastuzumab Pertuzumab Docetaxel Epirubicin Cyclophosphamid... | 18 Years - 70 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | NCT00551421 | Adenocarcinoma ... Adenocarcinoma ... Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... | pertuzumab cetuximab irinotecan hydr... immunohistochem... fluorescence in... gene expression... mutation analys... polymerase chai... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | NCT03894007 | Early-stage Bre... HER2-positive B... | Docetaxel Carboplatin Trastuzumab Pertuzumab Epirubicin Cyclophosphamid... Atezolizumab Trastuzumab emt... Paclitaxel | 18 Years - | Karolinska University Hospital | |
| Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer | NCT01669239 | Breast Cancer | Liposomal Doxor... | 18 Years - 74 Years | SOLTI Breast Cancer Research Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
